Why is Krebs Biochem falling/rising?

As of 15-Jul, Krebs Biochemicals & Industries Ltd is experiencing a price increase, currently at Rs 84.15, reflecting a rise of Rs 3.63 or 4.51%. Today's performance indicates that the stock has outperformed its sector by 3.26%, although it has shown erratic trading patterns, not trading on one day out of the last 20. The stock's intraday high reached Rs 84.15, but it has been trading below its 5-day, 20-day, and 200-day moving averages, despite being above the 50-day and 100-day averages. The stock has faced significant challenges, including a negative book value, a high debt-to-equity ratio, and poor long-term growth metrics, which have contributed to its overall weak fundamental strength. Additionally, the company has reported negative results for the last two consecutive quarters, with a notable decline in profits.
In the broader market context, Krebs Biochem has underperformed against the benchmark, with a year-to-date return of -9.03% compared to the Sensex's +5.67%. Over the past three years, the stock has consistently lagged behind the benchmark, generating negative returns while the Sensex has seen substantial growth. This underperformance, coupled with falling investor participation and a significant drop in delivery volume, suggests a lack of confidence among investors, despite the recent price increase. The overall market sentiment remains cautious due to the company's financial instability and negative EBITDA, which may overshadow any short-term gains.